Plasma Resuscitation for Thermal Burns
(PREEVEnT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether starting plasma resuscitation (a type of fluid replacement using plasma) quickly after a severe burn is more effective than usual methods. It targets individuals with large second or third-degree burns covering at least 20% of their body. The goal is to determine if this approach reduces complications and deaths. Individuals with severe burns requiring treatment in a burn ICU might be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to a potentially groundbreaking treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that plasma resuscitation is likely to be safe for humans?
Studies have shown that using plasma to treat burn patients is generally safe. Research indicates that plasma does not cause harmful changes in blood clotting or bleeding in these patients, meaning plasma treatment is usually well-tolerated.
Replacing lost fluids is a standard treatment for people with serious burns to prevent complications. Plasma resuscitation, a type of fluid replacement, uses plasma, a component of blood. While more research is always helpful, current evidence supports the safety of plasma in treating burns.12345Why do researchers think this study treatment might be promising?
Unlike the standard care for burn resuscitation, which typically involves fluids like saline or lactated Ringer's solution, plasma resuscitation offers a unique approach. Researchers are excited about this treatment because it uses plasma to potentially improve fluid management and stabilize patients more effectively after severe burns. Plasma contains proteins and clotting factors that could help reduce complications and improve healing, showing promise for better outcomes than traditional fluid resuscitation methods.
What evidence suggests that plasma resuscitation is effective for thermal burns?
Research has shown that starting plasma treatment early is crucial for patients with severe burns. In this trial, participants in the "Early Plasma Resuscitation" arm will receive plasma resuscitation initiated in the emergency department over approximately four hours. Studies indicate that timely fluid administration can reduce complications and improve recovery, such as lowering the risk of organ failure and death. This is particularly important for burns covering more than 20% of an adult's body. Plasma treatment restores blood volume and improves circulation after a burn, aiding the body's healing process. Although more research is needed, early findings suggest that plasma treatments do not increase the risk of blood clots, making them a safe option for treating severe burns.13456
Who Is on the Research Team?
Jason Sperry, MD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
The PREEVEnT trial is for adults who have suffered large second or third degree burns covering at least 20% of their body and require fluid replacement therapy. The study seeks participants immediately upon arrival to an emergency department or burn unit.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Early Plasma Resuscitation
Subjects receive early plasma resuscitation initiated in the emergency department/burn resuscitation area over an approximate 4-hour period from the time of randomization
Standard Care
Subjects receive resuscitation following individual site standard burn resuscitation practice
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Plasma Resuscitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jason Sperry
Lead Sponsor
United States Department of Defense
Collaborator